AR061669A1 - Aplicacion de alta frecuencia de terapia con toxina botulinica - Google Patents

Aplicacion de alta frecuencia de terapia con toxina botulinica

Info

Publication number
AR061669A1
AR061669A1 ARP070102861A ARP070102861A AR061669A1 AR 061669 A1 AR061669 A1 AR 061669A1 AR P070102861 A ARP070102861 A AR P070102861A AR P070102861 A ARP070102861 A AR P070102861A AR 061669 A1 AR061669 A1 AR 061669A1
Authority
AR
Argentina
Prior art keywords
high frequency
frequency therapy
therapy application
botulin toxin
composition
Prior art date
Application number
ARP070102861A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061669(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR061669A1 publication Critical patent/AR061669A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente se refiere a métodos para tratar enfermedades y trastornos mediante la administracion de una composicion que contiene al componente neurotoxico de un complejo de toxina Clostridium botulinum, en donde la composicion carece de cualquier otra proteína del complejo de toxina Clostridium botulinum y, en donde la composicion se administra en intervalos cortos y/o en dosis elevadas. Uso.
ARP070102861A 2006-06-29 2007-06-27 Aplicacion de alta frecuencia de terapia con toxina botulinica AR061669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81775606P 2006-06-29 2006-06-29

Publications (1)

Publication Number Publication Date
AR061669A1 true AR061669A1 (es) 2008-09-10

Family

ID=38462381

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102861A AR061669A1 (es) 2006-06-29 2007-06-27 Aplicacion de alta frecuencia de terapia con toxina botulinica

Country Status (17)

Country Link
US (3) US8557255B2 (es)
EP (2) EP2484373A1 (es)
JP (2) JP5897784B2 (es)
KR (3) KR20150126979A (es)
CN (1) CN101460190A (es)
AR (1) AR061669A1 (es)
AU (1) AU2007264008B2 (es)
BR (1) BRPI0713061A2 (es)
CA (1) CA2654214C (es)
CL (1) CL2007001911A1 (es)
IL (1) IL195201A (es)
MX (1) MX2009000253A (es)
RU (1) RU2453333C2 (es)
TW (1) TWI519310B (es)
UY (1) UY30450A1 (es)
WO (1) WO2008000490A1 (es)
ZA (1) ZA200808491B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CN101687018A (zh) * 2007-06-01 2010-03-31 德国麦氏大药厂 基于肉毒毒素的神经毒成分供应温度-稳定性固体肌肉松弛剂的方法
US7473429B1 (en) * 2007-07-27 2009-01-06 Renfroe J Ben Method for treatment of laminitis in animals
US8455459B2 (en) * 2007-08-02 2013-06-04 Medicis Pharmaceutical Corporation Method of applying an injectable filler
US20090204101A1 (en) * 2007-08-20 2009-08-13 Wortzman Mitchell S Method of applying an injectable filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
JPWO2009123174A1 (ja) * 2008-03-31 2011-07-28 一般財団法人化学及血清療法研究所 Ａ２型ボツリヌス神経毒素製剤
AU2009286973B2 (en) 2008-08-29 2014-06-12 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
ES2426667T3 (es) * 2008-09-09 2013-10-24 Susanne Grafe Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano)
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2246065A1 (en) 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
MX2012004703A (es) * 2009-10-21 2012-06-08 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
EP2399601A1 (en) 2010-06-24 2011-12-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin therapy
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
RU2454170C1 (ru) * 2011-02-21 2012-06-27 Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации Способ лечения спастичности мышц у больных с позвоночно-спинномозговой травмой
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
MX2016001220A (es) * 2013-07-30 2016-05-24 Merz Pharma Gmbh & Co Kgaa Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo.
JP6498678B2 (ja) 2013-09-20 2019-04-10 エムディディティ・インコーポレイテッドＭｄｄｔ Ｉｎｃ． 運動障害の診断および処置
WO2015039206A1 (en) * 2013-09-20 2015-03-26 Mddt Inc. Diagnosing and treating movement disorders
EP3154572A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154635A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016170501A1 (en) * 2015-04-24 2016-10-27 Consiglio Nazionale Delle Ricerche A new therapeutic use of the botulinum neurotoxin serotype a
EP3579930A1 (en) * 2017-02-10 2019-12-18 De Maio Domingos, Mauricio Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same
AU2020226945A1 (en) * 2019-02-21 2021-07-22 Merz Pharma Gmbh & Co. Kgaa Novel uses of botulinum neurotoxin for the treatment of tremor
RU2721300C2 (ru) * 2019-10-17 2020-05-18 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ лечения нейрогенной дисфункции мочевого пузыря, проявляющейся функциональной инфравезикальной обструкцией у женщин
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
EP4045073A4 (en) 2019-10-18 2022-12-07 Penland Foundation BOTULINUM TOXIN FOR USE IN A TREATMENT
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
WO2021137667A1 (ko) * 2019-12-30 2021-07-08 주식회사 에이티지씨 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888977A (en) * 1973-02-01 1975-06-10 Murray J Sanders Modified neurotoxin
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
DE69435235D1 (de) * 1993-06-10 2009-10-15 Allergan Inc Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
EP1366770B1 (en) * 1993-12-28 2005-07-27 Allergan, Inc. Use of the neurotoxic component of botulinum toxin for treating muscle-associated pain
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2336924T5 (es) * 1997-07-15 2014-04-30 The Regents Of The University Of Colorado Uso de toxina botulínica para el tratamiento de disfunción recalcitrante de evacuación
DE69930831T2 (de) * 1998-07-07 2006-11-30 Sun Chemical Corp. Kationisch härtbare lithographische druckfaben mit einem geringen gehalt an fl üchtigen organischen verbindungen
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
WO2000016245A1 (en) 1998-09-11 2000-03-23 Quid Technologies Llc Method and system for biometric recognition based on electric and/or magnetic properties
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6348434B1 (en) * 1999-07-01 2002-02-19 Basf Aktiengesellschaft Herbicidal emulsifiable concentrate
US20030180289A1 (en) * 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
JP2003512603A (ja) 1999-10-05 2003-04-02 テクノロジィ ファイナンス コーポレイション（プロプライエタリー） リミテッド 回転軸におけるトルクによるねじれの測定
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6533066B1 (en) 1999-10-14 2003-03-18 Rose Manufacturing Company Lanyard with integral fall arrest energy absorber
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
KR100602308B1 (ko) * 2001-07-27 2006-07-18 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지 여드름의 치료 또는 예방을 위한 보툴리눔 독소
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US20050106183A1 (en) * 2002-01-31 2005-05-19 Lamb Gregory B. Method of treating pain
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20030224020A1 (en) * 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JPWO2004016783A1 (ja) 2002-08-06 2006-01-19 株式会社ジェノックス創薬研究所 アトピー性皮膚炎の検査方法
US7824693B2 (en) * 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
CA2496005C (en) * 2002-08-19 2013-07-23 Ira Sanders Use of botulinum toxin for the treatment of fine wrinkles and pore size
US20040115222A1 (en) * 2002-09-06 2004-06-17 Michael Kane Method for reduction of wrinkles
DE50313304D1 (de) * 2002-09-10 2011-01-20 Siemens Ag Verfahren zur Kontrolle von Übertragungsressourcen eines paketorientierten Kommunikationsnetzes bei Topologieänderungen
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20050042775A1 (en) * 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US20050144029A1 (en) * 2003-12-31 2005-06-30 Rakowski Richard R. Systems and methods for aesthetic improvement
WO2005067967A1 (en) * 2004-01-05 2005-07-28 Botulinum Toxin Research Associates, Inc. Methods of using botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion)
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
CN101005853B (zh) * 2004-07-26 2011-05-04 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
CA2580122A1 (en) * 2004-09-27 2006-04-06 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in tissue healing
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
PL1830872T3 (pl) * 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CA2597244A1 (en) * 2005-03-03 2006-09-14 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
WO2008039245A2 (en) * 2006-04-27 2008-04-03 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CN101687018A (zh) * 2007-06-01 2010-03-31 德国麦氏大药厂 基于肉毒毒素的神经毒成分供应温度-稳定性固体肌肉松弛剂的方法
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
US9038912B2 (en) * 2007-12-18 2015-05-26 Microsoft Technology Licensing, Llc Trade card services
AU2009286973B2 (en) * 2008-08-29 2014-06-12 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
WO2010094463A1 (en) * 2009-02-19 2010-08-26 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
MX2011013014A (es) * 2009-07-02 2012-01-27 Merz Pharma Gmbh & Co Kgaa Neurotoxinas que exhiben actividad biologica acortada.
US9310386B2 (en) * 2010-01-22 2016-04-12 Merz Pharma Gmbh & Co. Kgaa In vitro assay for quantifying clostridial neurotoxin activity
AU2012334076A1 (en) * 2011-11-09 2014-05-15 Merz Pharma Gmbh & Co. Kgaa Modified neurotoxins with poly-Glycine and uses thereof
MX2016001220A (es) * 2013-07-30 2016-05-24 Merz Pharma Gmbh & Co Kgaa Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo.

Also Published As

Publication number Publication date
RU2453333C2 (ru) 2012-06-20
CA2654214A1 (en) 2008-01-03
US20150290303A1 (en) 2015-10-15
KR20150126979A (ko) 2015-11-13
IL195201A0 (en) 2009-08-03
KR20140142377A (ko) 2014-12-11
JP2014015476A (ja) 2014-01-30
UY30450A1 (es) 2009-04-30
US20080003241A1 (en) 2008-01-03
US20140010803A1 (en) 2014-01-09
EP2484373A1 (en) 2012-08-08
CL2007001911A1 (es) 2008-03-14
AU2007264008B2 (en) 2012-06-28
US8557255B2 (en) 2013-10-15
TW200819140A (en) 2008-05-01
IL195201A (en) 2015-11-30
EP2032157A1 (en) 2009-03-11
BRPI0713061A2 (pt) 2012-04-10
TWI519310B (zh) 2016-02-01
AU2007264008A1 (en) 2008-01-03
RU2009102848A (ru) 2010-08-10
JP5897784B2 (ja) 2016-03-30
CN101460190A (zh) 2009-06-17
MX2009000253A (es) 2009-01-22
ZA200808491B (en) 2009-11-25
US9095523B2 (en) 2015-08-04
KR20090027732A (ko) 2009-03-17
CA2654214C (en) 2023-07-04
WO2008000490A1 (en) 2008-01-03
JP2009541396A (ja) 2009-11-26
US9572871B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
AR061669A1 (es) Aplicacion de alta frecuencia de terapia con toxina botulinica
PE20190205A1 (es) Uso de inhibidores de miostatina y terapias de combinacion
BR112014009785A8 (pt) método para tratar ou reduzir efp
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112015025711A8 (pt) uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros
CO6751277A2 (es) Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes
ECSP13013007A (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
BRPI0720588B8 (pt) derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
NZ700623A (en) Botulinum toxin dosage regimen for chronic migraine prophylaxis
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015026122A8 (pt) agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
CL2011000553A1 (es) Metodo de tratamiento de esclerosis multiple progresiva, que comprende administrar un anticuerpo anti-cd20 a un paciente con edad inferior a 55 años y/o con lesiones que tiñen con gadolinio y/o con al menos un aumento de 1 punto edss y/o con un puntaje msss superior a 5 puntos; metodo de diagnostico; y articulo manufacturado.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
BR112014010590A2 (pt) 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112013032456A2 (pt) anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
BR112018014467A2 (pt) tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling

Legal Events

Date Code Title Description
FB Suspension of granting procedure